S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
NASDAQ:AEMD

Aethlon Medical (AEMD) Stock Price, News & Analysis

$1.72
+0.01 (+0.58%)
(As of 02:27 PM ET)
Today's Range
$1.67
$1.74
50-Day Range
$1.63
$1.99
52-Week Range
$1.40
$7.20
Volume
11,995 shs
Average Volume
8,638 shs
Market Capitalization
$4.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Aethlon Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
481.4% Upside
$10.00 Price Target
Short Interest
Healthy
0.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Aethlon Medical in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.98) to ($5.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.69 out of 5 stars

AEMD stock logo

About Aethlon Medical Stock (NASDAQ:AEMD)

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.

AEMD Stock Price History

AEMD Stock News Headlines

Aethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.com
Aethlon Medical Inc
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Aethlon Medical Inc (AEMD)
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Aethlon Medical Q3 2024 Earnings Preview
Earnings Preview: Aethlon Medical
Maxim Group Keeps Their Hold Rating on Aethlon Medical (AEMD)
A Preview Of Aethlon Medical's Earnings
See More Headlines
Receive AEMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aethlon Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
6/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:AEMD
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+488.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-12,030,000.00
Pretax Margin
-2,133.97%

Debt

Sales & Book Value

Annual Sales
$570,000.00
Book Value
$6.56 per share

Miscellaneous

Free Float
2,515,000
Market Cap
$4.45 million
Optionable
Optionable
Beta
1.89
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Guy F. Cipriani BS (Eng.) (Age 54)
    MBA, Chief Operating Officer
    Comp: $347.5k
  • Dr. Steven P. LaRosa M.D. (Age 57)
    Chief Medical Officer
    Comp: $430k
  • Mr. James B. Frakes M.B.A. (Age 67)
    Interim CEO, CFO, Secretary & Director
    Comp: $385k
  • Dr. Lee D. Arnold Ph.D. (Age 64)
    Chief Scientific Officer

AEMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Aethlon Medical stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aethlon Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEMD shares.
View AEMD analyst ratings
or view top-rated stocks.

What is Aethlon Medical's stock price target for 2024?

1 Wall Street analysts have issued 1 year price objectives for Aethlon Medical's stock. Their AEMD share price targets range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 481.4% from the stock's current price.
View analysts price targets for AEMD
or view top-rated stocks among Wall Street analysts.

How have AEMD shares performed in 2024?

Aethlon Medical's stock was trading at $2.19 at the start of the year. Since then, AEMD stock has decreased by 21.5% and is now trading at $1.72.
View the best growth stocks for 2024 here
.

Are investors shorting Aethlon Medical?

Aethlon Medical saw a increase in short interest in March. As of March 15th, there was short interest totaling 9,900 shares, an increase of 33.8% from the February 29th total of 7,400 shares. Based on an average daily trading volume, of 11,900 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.4% of the shares of the stock are sold short.
View Aethlon Medical's Short Interest
.

When is Aethlon Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024.
View our AEMD earnings forecast
.

How were Aethlon Medical's earnings last quarter?

Aethlon Medical, Inc. (NASDAQ:AEMD) released its quarterly earnings data on Wednesday, February, 14th. The medical equipment provider reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $0.14.

When did Aethlon Medical's stock split?

Aethlon Medical shares reverse split on the morning of Thursday, October 5th 2023. The 1-10 reverse split was announced on Wednesday, October 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Aethlon Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aethlon Medical investors own include Amarin (AMRN), Nokia Oyj (NOK), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), CRISPR Therapeutics (CRSP), Novavax (NVAX), Organigram (OGI), AT&T (T) and

Who are Aethlon Medical's major shareholders?

Aethlon Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.81%), Vanguard Group Inc. (0.85%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of Aethlon Medical?

Shares of AEMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AEMD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners